Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.

Endocrinol Diabetes Metab · 2026 · PMC13402857 · PMID 42504019

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Also, although the change in ALT level did not reach statistical significance, a decreasing trend was observed among patients with NAFLD compared with the control group [ 19 ].

also in 47,180 other papers

a nonsignificant trendno p-value reported

Comparison With Previous Studies The present meta‐analysis showed that in patients with MASLD, empagliflozin significantly reduced serum AST, ALT and GGT levels, with a nonsignificant trend toward lower ALP.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.